151
|
Jang JY, Ahn JH, Bae JS, Kang MG, Kim K, Park HW, Koh JS, Park Y, Hwang SJ, Kwak CH, Hwang JY, Jeong YH. P3637Relationship between serial measurements of NT-proBNP and cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Increased level of natriuretic peptides has been known as an important predictors of adverse cardiovascular (CV) outcomes in patients with acute coronary syndrome (ACS). We sought to evaluate clinical implication of N-terminal pro-brain natriuretic peptide (NT-proBNP) measured at initial and follow-up periods.
Methods
Serial NT-proBNP levels (on-admission and one-month post-PCI) were measured in ACS patients undergoing PCI (n=2,290). High NT-proBNP levels were determined according to the predefined age-specific criteria. Patients were stratified into 4 groups according to NT-proBNP levels (on-admission & one-month): (1) normal-normal group (n=1234, 53.9%); (2) high–normal group (n=257, 11.2%); (3) normal-high group (n=376, 16.4%); and (4) high-high group (n=423, 18.5%). Clinical events were defined as all-cause death and MACE (a composite of CV death, non-fatal MI, and ischemic stroke).
Results
With a median follow-up of 35.9 (IQR: 16.8, 54.5) months, all-cause death and MACE were occurred in 4.1% and 7.2%, respectively. NT-proBNP on-admission vs. at one-month did not differ significantly (median 391.6 [IQR: 143.9, 1402.3] vs. median 619.1 [IQR 240.1, 1616.1]; p=0.622), but the prevalence of high NT-proBNP was increased over time (25.3% to 34.9%; p<0.001). The rates of all-cause death and MACE significantly increased only in the high-high group compared with other groups (log-rank test, all p values <0.001, Figure). After adjustment, the high-high group remained significantly risky in terms with the occurrence of all-cause death (HR, 2.99; 95% CI, 1.65 to 5.41; p<0.001) and MACE (HR, 1.96; 95% CI, 1.28 to 3.01; p=0.002).
Figure 1
Conclusion
Serial measurements of NT-proBNP at on-admission and follow-up can help to stratify the risks of all-cause death and adverse CV events following PCI in ACS patients. About two-fifths of patients having high NT-proBNP level during hospitalization can be classified into the low-risk group for all-cause death and adverse CV events.
Acknowledgement/Funding
None
Collapse
|
152
|
Yamashita Y, Yoshikawa Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Oi M, Murata K, Tsuyuki Y, Sakamoto J, Shiomi H, Makiyama T, Ono K, Kimura T. P5593The association of recurrence and bleeding events with mortality after venous thromboembolism: from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background/Introduction
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), has a long-term risk for recurrence, which can be prevented by anticoagulation therapy. The duration of anticoagulation therapy after VTE should be based on the balance between risks of recurrent VTE and bleeding. However, there is uncertainty about the impact of these events on subsequent mortality.
Purpose
We sought to evaluate the impact of recurrent VTE events and bleeding events on subsequent mortality in patients with VTE in a large retrospective observational database in Japan.
Methods
We evaluated the association of recurrent VTE and major bleeding with mortality among 3026 patients in the COMMAND VTE Registry. We estimated the risks of recurrent VTE events and major bleeding events for subsequent all-cause death with the multivariable Cox proportional hazard model. We incorporated the recurrent VTE events and major bleeding events during follow-up into the multivariable Cox model as time-updated covariates together with the clinically-relevant 16 risk-adjusting factors. We expressed the adjusted risks of each covariate as hazard ratios (HR) and their 95%confidence intervals (CI). Furthermore, to assess the risks of recurrent PE and recurrent DVT events for subsequent all-cause death respectively, we divided recurrent VTE events into recurrent PE (PE with or without DVT) and recurrent DVT (DVT only), and incorporated these events as well as major bleeding events into the multivariable Cox model as time-updated covariates.
Results
In the current study population, the mean age was 67 years, 61% were women, and mean body weight and body mass index were 57.9 kg and 23.2 kg/m2, respectively. During the median follow-up period of 1,218 days, 763 patients died, 225 patients developed recurrent VTE events, and 274 patients developed major bleeding events. The time-updated multivariable Cox proportional hazard model revealed that both the recurrent VTE events and the major bleeding events were strongly associated with subsequent mortality risk (recurrent VTE events: HR 3.24, 95% CI 2.57–4.08, P<0.001; major bleeding events: HR 3.53, 95% CI 2.88–4.31, P<0.001). Both the recurrent PE events and the recurrent DVT events were associated with subsequent mortality risk with the numerically greater magnitude of effect with the recurrent PE events than with the recurrent DVT events (recurrent PE events: HR 4.42, 95% CI 3.28–5.95, P<0.001; recurrent DVT events: HR 2.42, 95% CI 1.75–3.36, P<0.001).
Conclusions
In the real-world patients with VTE, both recurrent VTE events and major bleeding events were strongly associated with subsequent mortality risk with the comparable effect size. Recurrent PE and recurrent DVT events were also associated with increased risks for mortality, although the magnitude of the effect on mortality was numerically greater with the recurrent PE events than with the recurrent DVT events.
Acknowledgement/Funding
Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation
Collapse
|
153
|
Meattini I, Livi L, Kim K, Kim J, Jung W, Olmetto E, Desideri I, Saieva C, Becherini C, Salvestrini V, Fourquet A, Kirova Y, Poortmans P. Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: A multi-center comparative study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
154
|
Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Oi M, Murata K, Tsuyuki Y, Sakamoto J, Yoshikawa Y, Shiomi H, Makiyama T, Ono K, Kimura T. P3847Deep vein thrombosis in upper extremities: clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Pulmonary embolism (PE) is caused by blockage of pulmonary arteries by thrombus. The sources of thrombus are thought to be mostly veins in lower extremities, whereas deep vein thrombosis (DVT) in upper extremities rarely occurs spontaneously. Recent studies reported that DVT in upper extremities might have significant complications, and DVT in upper extremities could be increasing. However, there is a paucity of data on patients with DVT in upper extremities, leading to uncertainty in optimal treatment strategies including anticoagulation therapy.
Purpose
We sought to evaluate the clinical characteristics, management strategies, and long-term outcomes of patients with DVT in upper extremities in a large observational database in Japan.
Methods
The COMMAND VTE Registry is a multicenter registry enrolling 3027 consecutive patients with acute symptomatic venous thromboembolism (VTE) objectively confirmed by imaging examination or by autopsy among 29 centers in Japan between January 2010 and August 2014. The current study population consisted of 2498 patients with DVT in upper or lower extremities, after excluding 381 patients with PE only, 144 patients who had thrombus in locations other than upper or lower extremities, and 4 patients with DVT in both upper and lower extremities. The study patients were divided into 2 groups: patients with DVT in upper extremities and patients with DVT in lower extremities. We compared the clinical characteristics, management strategies and long-term outcomes between the 2 groups.
Results
There were 74 patients (3.0%) with upper extremities DVT and 2498 patients (97%) with lower extremities DVT. Patients with upper extremities DVT more often had active cancer at diagnosis (58%) and central venous catheter use (22%). The proportion of concomitant PE at diagnosis was lower in patients with upper extremities DVT than in those with lower extremities DVT (14% and 51%, P<0.001). Discontinuation of anticoagulation therapy was more frequent in patients with upper extremities DVT (63.8% and 29.8% at 1-year, P<0.001). The cumulative 3-year incidence of recurrent VTE was not different between the 2 groups (9.8% and 7.4%, P=0.43) (Figure). After adjusting confounders, the risks of upper extremities DVT relative to lower extremities DVT for recurrent VTE remained insignificant (HR 0.94, 95% CI 0.36–2.01, P=0.89).
Kaplan-Meier event curves for recurrence
Conclusions
The prevalence of patients with DVT in upper extremities was 3.0% in the current large-scale real-world registry. Patients with DVT in upper extremities more often had active cancer at diagnosis and central venous catheter use as a transient risk factor for VTE, and less often had concomitant PE. Patients with DVT in upper extremities had similar long-term risk for recurrent VTE as those with DVT in lower extremities despite shorter duration of anticoagulation.
Acknowledgement/Funding
Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation
Collapse
|
155
|
Kim K, Park J. Electrodiagnostic characteristics of upper lumbar stenosis: Discrepancy between neurological and structural levels. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
156
|
Yoshikawa Y, Yamashita Y, Mabuchi H, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Oi M, Kobayashi Y, Toyofuku M, Tada T, Murata K, Sakamoto J, Kimura T. P3846The association between statin prescription, recurrent venous thromboembolism and bleeding events: from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Statin prevents occurrence and recurrence of atherosclerotic events. With regard to venous thromboembolism (VTE), a randomized controlled trial suggested that statin reduced occurrence of VTE, whereas its usefulness as secondary prevention of VTE remains to be elucidated.
Purpose
This study aimed to assess the association between statin prescription, recurrent VTE and bleeding events in patients with VTE.
Methods
The COMMAND VTE Registry is a multicentre registry enrolling consecutive 3027 patients with acute symptomatic VTE among 29 centres in Japan. We divided the cohort into the patients who were prescribed statin (N=437) and those not (N=2590), and compared the two groups. We assessed hazard ratios (HRs) of those with statin relative to those without for long-term clinical outcomes (recurrent symptomatic VTE and International Society of Thrombosis and Hemostasis [ISTH] major bleeding). Because the durations of anticoagulation therapy were widely different between the two groups, we constructed Cox's proportional hazard model incorporating status of anticoagulation during the follow-up period as a time-varying covariate. Also, because the incidences of death were strikingly different between the two groups due to the difference in the prevalence of active cancer, we used Fine-Gray's subdistribution hazard model in the presence of competing risks. We incorporated clinically relevant factors into these two models as covariates (10 factors for recurrent VTE and 11 for major bleeding).
Results
The statin group was significantly older than the non-statin group (statin 71.2±11.8 vs. non-statin 66.5±15.8, P<0.001). The prevalence of active cancer in the statin group was less than one-half of that in the non-statin group (12% vs. 25%, P<0.001), and the cumulative 3-year incidence of death was significantly lower in the statin group than in the non-statin group (12.8% vs. 26.1%, log-rank P<0.001). The table shows the adjusted HRs of the statin group relative to the non-statin group. The HRs of the statin group relative to non-statin group for recurrent VTE were significantly low, but those for major bleeding were insignificant.
Adjusted hazard ratios Outcome measures Model 1 P value Model 2 P value Adjusted HR [95% CI] Adjusted HR [95% CI] Recurrent VTE 0.59 [0.36–0.98] 0.042 0.53 [0.32–0.89] 0.02 Major bleeding 0.87 [0.60–1.24] 0.43 0.997 [0.69–1.43] 0.99 Model 1 derived from Cox's model with time-varying covariate of anticoagulation status. Model 2 derived from Fine-Gray's model.
Study flowchart
Conclusions
Prescription of satin was associated with significantly low risks for recurrent VTE, whereas that was not for major bleeding events. Statin could be a potential treatment option for secondary prevention of VTE.
Collapse
|
157
|
Hwang Y, Jeon J, Cho S, Kim K, Jheon S. P2.17-37 Prognostic Implication of Surgical Treatment for the Dominant Lung Adenocarcinoma Associated with Part-Solid Nodules. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
158
|
Kim Y, Kim C, Lee S, Lee H, Kim H, Kim K, Sun J, Ahn J, Ahn M, Park K. OA14.07 Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
159
|
Nishimoto Y, Yamashita Y, Morimoto T, Saga S, Amano H, Takase T, Hiramori S, Kim K, Oi M, Akao M, Kobayashi Y, Toyofuku M, Izumi T, Sato Y, Kimura T. P5592Thrombolysis with tissue plasminogen activator for patients with acute pulmonary embolisms in the real world: from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
There is still uncertainty about the optimal usage of thrombolysis for acute pulmonary embolisms (PEs), leading to widely varying usage of thrombolysis in the real world. However, these have not been fully evaluated yet.
Purpose
We sought to evaluate the management strategies and clinical outcomes of thrombolysis for acute PEs in the real world.
Methods
The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic venous thromboembolisms in Japan between January 2010 and August 2014. The present study population consisted of 1,549 patients with PEs who received tissue plasminogen activator (t-PA) thrombolysis (N=180, 12%), or those who did not (N=1,369). The effectiveness outcome was all-cause death. The safety outcome was major bleeding. We used a multivariable logistic regression analysis to estimate the odds ratio (OR) and 95% confidence intervals (CI), to adjust clinically relevant confounders (age, sex, history of major bleeding, active cancer, and anemia). Additionally, we conducted stratified analysis by clinical severity, and we also evaluated clinical outcomes according to dosages of t-PA.
Results
Patients with t-PA thrombolysis were younger, and more frequently had higher body weight, but less frequently had active cancer, history of major bleeding, and anemia. More than half of patients with t-PA thrombolysis were patients with mild PEs, and the proportions of t-PA thrombolysis varied widely across the participating centers. More than half of patients received low-dose of t-PA (<20,000 IU/kg). As for the effectiveness, 9 (5.0%) patients in the t-PA thrombolysis group and 95 (6.9%) patients in the non t-PA thrombolysis group died at 30 days (Crude OR, 0.71; 95% CI 0.35–1.42, P=0.33). As for the safety, 7 (3.9%) patients in the t-PA thrombolysis group and 22 (1.6%) patients in the non t-PA thrombolysis group experienced major bleeding events at 10 days (Crude OR, 2.48; 95% CI 1.04–5.88, P=0.04). T-PA thrombolysis group had a significantly higher risk for 10-day major bleeding (Adjusted OR, 4.01; 95% CI 1.57–10.2, P=0.004), but not a lower risk for 30-day mortality (Adjusted OR, 1.10; 95% CI 0.53–2.28, P=0.79), although the risk for 30-day mortality was significantly lower in those with severe PEs (Adjusted OR, 0.36; 95% CI 0.15–0.88, P=0.02). After adjusting confounders, the 10-day major bleeding risk of the low-dose of t-PA group relative to the standard-dose of t-PA group tended to be lower (Adjusted OR, 0.07; 95% CI 0.004–1.05, P=0.05).
Conclusions
In the present real-world registry, relatively large number of patients received t-PA thrombolysis with wide variation across the participating centers. T-PA thrombolysis was significantly associated with a higher risk for major bleeding, but not a lower risk for mortality, although there appeared to be a benefit of t-PA thrombolysis in decreasing the risk for mortality in patients with severe PEs.
Acknowledgement/Funding
Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation
Collapse
|
160
|
Murata K, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Kobayashi Y, Oi M, Tsuyuki Y, Sakamoto J, Nawada R, Onodera T, Kimura T. P6461The long-term clinical comparisons of symptomatic patients of pulmonary embolism with and those without deep vein thrombosis: from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), has significant morbidity and mortality. Acute PE, in particular, is fatal if we miss it, and symptomatic patients of PE sometimes have concomitant DVT.
Purpose
This study compared the risk of mortality in symptomatic patients of PE with and those without DVT in the long term.
Methods
The COMMAND VTE Registry is a multicenter registry enrolling consecutive 3027 patients with acute symptomatic VTE objectively confirmed by imaging examination or by autopsy among 29 centers in Japan between January 2010 and August 2014. Patients with both PE and DVT (N=1334) were regarded as PE patients, and the current study population consisted of 1715 PE patients and 1312 DVT patients.
Results
There were 1203 symptomatic patients of PE, including 381 without and 822 with DVT. In our cohort, the mean age was 67.9±14.9 years, 63% was female, 44% had hypertension, 12% diabetes mellitus, 5% history of VTE. There were 20% of active cancer. Baseline characteristics were well matched except for dyslipidemia (18% vs. 23%, p=0.021) and atrial fibrillation (8% vs. 5%, p=0.045). Patients without DVT had a more severe clinical presentation compared to those with DVT, including hypoxemia, shock and arrest. Moreover, Initial parenteral anticoagulation therapy in the acute phase was administered less frequently in patients without DVT (89% vs. 96%, P=0.0001). Two groups received thrombolysis (20% vs. 26%, P=0.18) and mechanical supports (Ventilator 14% vs. 5%, p<0.001, PCPS 5% vs. 3%, p<0.001, respectively). During follow-up, 93 (8%) patients experienced recurrent VTE events and 98 (8%) major bleeding events, and 323 (27%) patients died. The most frequent cause of death was cancer (11%). There were a significant differences in the cumulative incidences of all-cause death between the groups (32% vs. 24%, P=0.006), whereas there was significant difference in VTE-related death (13% vs. 4%, p<0.001). Estimated freedom rates from death for patients of PE without and those with DVT were as follows: 88% vs 99% at 10-day, 86% vs 95% at 1-month, 75% vs 83% at 1-year, and 64% vs 71% at 5-year, respectively.
Landmark analysis
Conclusions
In symptomatic patients of PE, there was a difference in mortality between groups, but no difference in recurrent VTE. Patients without DVT had a more severe clinical presentation compared to those with DVT, and many VTE-related deaths in the acute phase. The one-month mortality rate differed statistically between groups, but there was no significant difference in long-term survival beyond one month. Most of deaths were due to underlying diseases, mainly cancer, and less commonly due to VTE in the long term.
Acknowledgement/Funding
Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation
Collapse
|
161
|
Oi M, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Kobayashi Y, Tada T, Murata K, Murata K, Toyofuku M, Jinnnai T, Kaitani K, Kimura T. P2770Clinical characteristics and outcomes of venous thromboembolism according to patients with versus without atrial fibrillation: from the COMMAND VTE Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background/Introduction
Oral anticoagulants are widely used for the treatment and second prevention of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF). VTE and AF are common diseases and these sometimes might coexist. However, there are few reports about the relationship between VTE and AF.
Purpose
We sought to evaluate the clinical characteristics and outcomes in VTE patients with AF.
Methods
The COMMAND VTE Registry is a multicenter registry enrolling consecutive 3027 patients with acute symptomatic VTE objectively confirmed by imaging examination or by autopsy among 29 centers in Japan between January 2010 and August 2014. The current study population consisted of 129 patients with AF (AF group) and 2898 patients without AF (non-AF group). We compared the clinical characteristics, management strategies and long-term outcomes between the 2 groups.
Results
The AF group was older (mean age: 75.3 vs. 66.8 years, P<0.001), and more often had co-morbidities such as hypertension (54.3% vs. 37.7%, P<0.001), diabetes mellitus (20.2% vs. 12.4%, P=0.01), chronic kidney disease (28.7% vs. 18.5%, P=0.004), heart failure (28.7% vs. 18.5%, P=0.004), history of stroke (20.2% vs. 8.4%, P<0.001), and history of major bleeding (12.4% vs. 7.4%, P=0.04) compared with the non-AF group, whereas there were no significant differences in the proportions of active cancer at diagnosis (18.6% vs. 23.2%, P=0.23) and pulmonary embolism at presentation (64.3% vs. 56.3%, P=0.07). The proportion of anticoagulation therapy beyond acute phase was not significantly different (94% vs. 93%, P=0.60), while the cumulative discontinuation rates of anticoagulation therapy was significantly lower in the AF group (26.9% vs. 43.4% at 3 years, Log-rank P=0.03). The cumulative 5-year incidences of recurrent VTE and major bleeding were not significantly different (Recurrent VTE: 7.6% vs. 10.6%, Log-rank P=0.89; Major bleeding: 18.6% vs. 11.8%, Log-rank P=0.07). After adjusting for potential confounders, the risks of the AF group relative to the non-AF group for recurrent VTE and major bleeding remained insignificant (HR 1.19, 95% CI 0.54–2.28, P=0.64; HR 1.28, 95% CI 0.73–2.06, P=0.37). The cumulative 5-year incidence of all-cause death was significantly higher in the AF-group (49.1% vs. 28.6%, Log-rank P<0.001). After adjusting for potential confounders, the risks of the AF group relative to the non-AF group for all-cause death remained significant (HR 1.63, 95% CI 1.23–2.15, P<0.001). The proportion of deaths due to cancer was lower in the AF group (30% vs. 55%, P<0.001), while the proportion of cardiac deaths was higher in the AF group (16.1% vs. 4.0%, P<0.001).
The outcomes of VTE patients with AF
Conclusions
The risks for recurrent VTE between patients with AF and those without AF were not significantly different, although patients with AF received longer-term anticoagulation therapy, whereas the risks for major bleeding tended to be higher in patients with AF.
Acknowledgement/Funding
Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation
Collapse
|
162
|
Montazerian H, Mohamed MGA, Montazeri MM, Kheiri S, Milani AS, Kim K, Hoorfar M. Permeability and mechanical properties of gradient porous PDMS scaffolds fabricated by 3D-printed sacrificial templates designed with minimal surfaces. Acta Biomater 2019; 96:149-160. [PMID: 31252172 DOI: 10.1016/j.actbio.2019.06.040] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 06/10/2019] [Accepted: 06/21/2019] [Indexed: 12/15/2022]
Abstract
In the present study, polydimethylsiloxane (PDMS) porous scaffolds are designed based on minimal surface architectures and fabricated through a low-cost and accessible sacrificial mold printing approach using a fused deposition modeling (FDM) 3D printer. The effects of pore characteristics on compressive properties and fluid permeability are studied. The results suggest that radially gradient pore distribution (as a potential way to enhance mechanically-efficient scaffolds with enhanced cell/scaffold integration) has higher elastic modulus and fluid permeability compared to their uniform porosity counterparts. Also, the scaffolds are fairly strain-reversible under repeated loading of up to 40% strain. Among different triply periodic minimal surface pore architectures, P-surface was observed to be stiffer, less permeable and have lower densification strain compared to the D-surface and G-surface-based pore shapes. The biocompatibility of the created scaffolds is assessed by filling the PDMS scaffolds using mouse embryonic fibroblasts with cell-laden gelatin methacryloyl which was cross-linked in situ by UV light. Cell viability is found to be over 90% after 4 days in 3D culture. This method allows for effectively fabricating biocompatible porous organ-shaped scaffolds with detailed pore features which can potentially tailor tissue regenerative applications. STATEMENT OF SIGNIFICANCE: Printing polymers with chemical curing mechanism required for materials such as PDMS is challenging and impossible to create high-resolution uniformly cured structures due to hard control on the base polymer and curing process. An interconnected porous mold with ordered internal architecture with complex geometries were 3D printed using low-cost and accessible FDM technology. The mold acted as a 3D sacrificial material to form internally architected flexible PDMS scaffolds for tissue engineering applications. The scaffolds are mechanically stable under high strain cyclic loads and provide enough pore and space for viably integrating cells within the gradient architecture in a controllable manner.
Collapse
|
163
|
Brown T, Titus P, Im K, Kim K. Design definition of the K-DEMO in-vessel blanket arrangement, blanket sector maintenance details and upper lever RM enclosure. FUSION ENGINEERING AND DESIGN 2019. [DOI: 10.1016/j.fusengdes.2019.02.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
164
|
Kim K, Chung B, Lee Y, Lee J, Hong K, Lew B, Sim W. 313 Different polyamine levels in the vertex and occipital hair of pattern hair loss patients. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
165
|
Kim K, Im E, Lew B, Lee M, Lee J, Paeng K, Chung B. 174 Changes in urine androgen and PG levels during finasteride treatment. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
166
|
Chang J, Choi S, Shin K, Park W, Kim K, Lee I, Yoon W, Cha J, Lee K, Kim J, Choi J, Ahn S, Ha B, Lee S, Kim W, Shin S, Kim Y. Radiation Practice Patterns and the Impact of Radiotherapy on Complications after Breast Reconstruction: A Multicenter Study (KROG 18-04). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
167
|
Alcorn S, Fiksel J, Hu C, Wright J, Kleinberg L, Levin A, Smith T, Cheng Z, Elledge C, Kim K, Rao A, Sloan L, Page B, Stinson S, Voong R, McNutt T, Bowers M, DeWeese T, Zeger S. Pilot Assessment of the BMET Decision Support Platform: A Tool to Improve Provider Survival Estimates and Selection of Prognosis-Appropriate Treatment for Patients with Symptomatic Bone Metastases. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
168
|
Kim J, Kim K, Shin K, Kim J, Kim S, Kim T, Kim Y, Park W, Kim J. M1 Neck Lymph Node Positive without Distant Metastasis in Breast Cancer: Comparison with Stage IIIc. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
169
|
Hwang J, Park N, Choi H, Hwang J, Lee S, Min D, Kim K, Park W. 564 Melasolv, a skin lightening compound with different mechanisms to regulate skin pigmentation. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
170
|
Oh E, Kim D, Cha Y, Chun S, Chie E, Kim K, Park J, Kim J, Yu J, Kim S, Nam T, Kim J. Evaluation of the New AJCC Staging System (8th edition) in Anal Cancer Patients Treated with Curative Chemoradiotherapy (KROG 18-05). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
171
|
Duong VT, Dang TT, Kim JP, Kim K, Ko H, Hwang CH, Koo KI. Twelve-day medium pumping into tubular cell-laden scaffold using a lab-made PDMS connector. Eur Cell Mater 2019; 38:1-13. [PMID: 31332770 DOI: 10.22203/ecm.v038a01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
In the current study, a method is proposed to supply culture medium into a two-layered cell-laden tubular scaffold in order to enhance cell proliferation, confluence, and viability. The two-layered cell-laden tubular scaffold was made of calcium-alginate mixed with fibroblast cells (NIH/3T3) using a lab-made double- coaxial laminar-flow generator. Afterwards, the tubular scaffold was connected to a syringe pump system using a polydimethylsiloxane (PDMS) micro-connector for long-term cell culture. Three medium pumping conditions were applied and compared: a heart-beat-mimicking pumping (20 µL/s, 1 s period, and 50 % pulse width), a continuous pumping (20 µL/s) and a non-pumping. Non-leaky connections between the tubular scaffolds and the micro-connector outlet were sustained for 13.5 ± 0.83 d in heartbeat-mimicking pumping and 11.8 ± 0.33 d in continuous pumping condition, due to the elasticity of the tubular scaffolds. Importantly, the two pumping conditions resulted in more cell proliferation, confluence, and viability than the non-pumping condition. Furthermore, analysis of newly-produced type-I collagen matrix indicated that the cells under the two pumping conditions formed a tissue-like structure. The proposed technique could further be applied to vascular co-culturing for vascular engineered tissue.
Collapse
|
172
|
Abbott B, Abbott R, Abbott T, Abraham S, Acernese F, Ackley K, Adams C, Adhikari R, Adya V, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar O, Aiello L, Ain A, Ajith P, Allen G, Allocca A, Aloy M, Altin P, Amato A, Ananyeva A, Anderson S, Anderson W, Angelova S, Antier S, Appert S, Arai K, Araya M, Areeda J, Arène M, Arnaud N, Arun K, Ascenzi S, Ashton G, Aston S, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader M, Bae S, Baker P, Baldaccini F, Ballardin G, Ballmer S, Banagiri S, Barayoga J, Barclay S, Barish B, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley J, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell A, Beniwal D, Berger B, Bergmann G, Bernuzzi S, Bero J, Berry C, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Bilenko I, Bilgili S, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard M, Blackburn J, Blair C, Tasson J, Taylor R, Tenorio R, Thies F, Thomas M, Thomas P, Thondapu S, Thorne K, Thrane E, Tiwari S, Blair D, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie C, Töyrä D, Travasso F, Traylor G, Blair R, Tringali M, Trovato A, Trozzo L, Trudeau R, Tsang K, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Bloemen S, Ueno K, Ugolini D, Unnikrishnan C, Urban A, Usman S, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, Bode N, van den Brand J, Van Den Broeck C, Vander-Hyde D, van Heijningen J, van der Schaaf L, van Veggel A, Vardaro M, Varma V, Vass S, Vasúth M, Boer M, Vecchio A, Vedovato G, Veitch J, Veitch P, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets A, Boetzel Y, Vine D, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin S, Wade A, Wade L, Wade M, Bogaert G, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang J, Wang W, Wang Y, Ward R, Bondu F, Warden Z, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein A, Weiss R, Weldon G, Bonilla E, Wellmann F, Wen L, Wessel E, Weßels P, Westhouse J, Wette K, Whelan J, Whiting B, Whittle C, Wilken D, Bonnand R, Williams D, Williamson A, Willis J, Willke B, Wimmer M, Winkler W, Wipf C, Wittel H, Woan G, Woehler J, Booker P, Wofford J, Worden J, Wright J, Wu D, Wysocki D, Xiao L, Yamamoto H, Yancey C, Yang L, Yap M, Boom B, Yazback M, Yeeles D, Yu H, Yu H, Yuen S, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Booth C, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhou M, Zhou Z, Zhu X, Zucker M, Zweizig J, Bork R, Pisarski A, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady P, Bramley A, Branchesi M, Brau J, Briant T, Briggs J, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks A, Brown D, Brunett S, Buikema A, Bulik T, Bulten H, Buonanno A, Buskulic D, Buy C, Byer R, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp J, Campbell W, Cannon K, Cao H, Cao J, Capocasa E, Carbognani F, Caride S, Carney M, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chakravarti K, Chamberlin S, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro B, Chen H, Chen X, Chen Y, Cheng HP, Cheong C, Chia H, Chincarini A, Chiummo A, Cho G, Cho H, Cho M, Christensen N, Chu Q, Chua S, Chung K, Chung S, Ciani G, Ciecielag P, Ciobanu A, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark J, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colgan R, Colleoni M, Collette C, Collins C, Cominsky L, Constancio M, Conti L, Cooper S, Corban P, Corbitt T, Cordero-Carrión I, Corley K, Cornish N, Corsi A, Cortese S, Costa C, Cotesta R, Coughlin M, Coughlin S, Coulon JP, Countryman S, Couvares P, Covas P, Cowan E, Coward D, Cowart M, Coyne D, Coyne R, Creighton J, Creighton T, Cripe J, Croquette M, Crowder S, Cullen T, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin S, D’Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier L, Dattilo V, Dave I, Davier M, Davis D, Daw E, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, DeMarchi L, Demos N, Dent T, De Pietri R, Derby J, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz M, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Donovan F, Dooley K, Doravari S, Dorosh O, Dorrington I, Downes T, Drago M, Driggers J, Du Z, Ducoin JG, Dupej P, Dwyer S, Easter P, Edo T, Edwards M, Effler A, Ehrens P, Eichholz J, Eikenberry S, Eisenmann M, Eisenstein R, Essick R, Estelles H, Estevez D, Etienne Z, Etzel T, Evans M, Evans T, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr W, Fauchon-Jones E, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer M, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira E, Ferreira T, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher R, Fishner J, Fitz-Axen M, Flaminio R, Fletcher M, Flynn E, Fong H, Font J, Forsyth P, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov V, Fulda P, Fyffe M, Gabbard H, Gadre B, Gaebel S, Gair J, Gammaitoni L, Ganija M, Gaonkar S, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime J, Giardina K, Giazotto A, Gill K, Giordano G, Glover L, Godwin P, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro J, Gopakumar A, Gorodetsky M, Gossan S, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green A, Green R, Gretarsson E, Groot P, Grote H, Grunewald S, Gruning P, Guidi G, Gulati H, Guo Y, Gupta A, Gupta M, Gustafson E, Gustafson R, Haegel L, Halim O, Hall B, Hall E, Hamilton E, Hammond G, Haney M, Hanke M, Hanks J, Hanna C, Hannam M, Hannuksela O, Hanson J, Hardwick T, Haris K, Harms J, Harry G, Harry I, Haskell B, Haster CJ, Haughian K, Hayes F, Healy J, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng I, Hennig J, Heptonstall A, Hernandez Vivanco F, Heurs M, Hild S, Hinderer T, Hoak D, Hochheim S, Hofman D, Holgado A, Holland N, Holt K, Holz D, Hopkins P, Horst C, Hough J, Hourihane S, Howell E, Hoy C, Hreibi A, Huerta E, Huet D, Hughey B, Hulko M, Husa S, Huttner S, Huynh-Dinh T, Idzkowski B, Iess A, Ingram C, Inta R, Intini G, Irwin B, Isa H, Isac JM, Isi M, Iyer B, Izumi K, Jacqmin T, Jadhav S, Jani K, Janthalur N, Jaranowski P, Jenkins A, Jiang J, Johnson D, Jones A, Jones D, Jones R, Jonker R, Ju L, Junker J, Kalaghatgi C, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner J, Kapadia S, Karki S, Karvinen K, Kashyap R, Kasprzack M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana N, Kéfélian F, Keitel D, Kennedy R, Key J, Khalili F, Khan H, Khan I, Khan S, Khan Z, Khazanov E, Khursheed M, Kijbunchoo N, Kim C, Kim J, Kim K, Kim W, Kim W, Kim YM, Kimball C, King E, King P, Kinley-Hanlon M, Kirchhoff R, Kissel J, Kleybolte L, Klika J, Klimenko S, Knowles T, Koch P, Koehlenbeck S, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth W, Kowalska I, Kozak D, Kringel V, Krishnendu N, Królak A, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey B, Lai K, Lam T, Landry M, Lane B, Lang R, Lange J, Lantz B, Lanza R, Lartaux-Vollard A, Lasky P, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche Y, Lee C, Lee H, Lee H, Lee H, Lee J, Lee K, Lehmann J, Lenon A, Leroy N, Letendre N, Levin Y, Leviton J, Li J, Li K, Li T, Li X, Lin F, Linde F, Linker S, Littenberg T, Liu J, Liu X, Lo R, Lockerbie N, London L, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lousto C, Lovelace G, Lower M, Lück H, Lumaca D, Lundgren A, Lynch R, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod D, Macquet A, Magaña-Sandoval F, Magaña Zertuche L, Magee R, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell G, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan A, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin I, Martin R, Martynov D, Mason K, Massera E, Masserot A, Massinger T, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann J, McCarthy R, McClelland D, McCormick S, McCuller L, McGuire S, McIver J, McManus D, McRae T, McWilliams S, Meacher D, Meadors G, Mehmet M, Mehta A, Meidam J, Melatos A, Mendell G, Mercer R, Mereni L, Merilh E, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers P, Miao H, Michel C, Middleton H, Mikhailov E, Milano L, Miller A, Miller A, Millhouse M, Mills J, Milovich-Goff M, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov V, Mitselmakher G, Mittleman R, Mo G, Moffa D, Mogushi K, Mohapatra S, Montani M, Moore C, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry C, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz E, Muratore M, Murray P, Nardecchia I, Naticchioni L, Nayak R, Neilson J, Nelemans G, Nelson T, Nery M, Neunzert A, Ng K, Ng S, Nguyen P, Nichols D, Nissanke S, Nocera F, North C, Nuttall L, Obergaulinger M, Oberling J, O’Brien B, O’Dea G, Ogin G, Oh J, Oh S, Ohme F, Ohta H, Okada M, Oliver M, Oppermann P, Oram RJ, O’Reilly B, Ormiston R, Ortega L, O’Shaughnessy R, Ossokine S, Ottaway D, Overmier H, Owen B, Pace A, Pagano G, Page M, Pai A, Pai S, Palamos J, Palashov O, Palomba C, Pal-Singh A, Pan HW, Pang B, Pang P, Pankow C, Pannarale F, Pant B, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone B, Pedersen C, Pedraza M, Pedurand R, Pele A, Penn S, Perez C, Perreca A, Pfeiffer H, Phelps M, Phukon K, Piccinni O, Pichot M, Piergiovanni F, Pillant G, Pinard L, Pirello M, Pitkin M, Poggiani R, Pong D, Ponrathnam S, Popolizio P, Porter E, Powell J, Prajapati A, Prasad J, Prasai K, Prasanna R, Pratten G, Prestegard T, Privitera S, Prodi G, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez P, Quintero E, Quitzow-James R, Raab F, Radkins H, Radulescu N, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez K, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze D, Ren W, Ricci F, Richardson C, Richardson J, Ricker P, Riles K, Rizzo M, Robertson N, Robie R, Robinet F, Rocchi A, Rolland L, Rollins J, Roma V, Romanelli M, Romano R, Romel C, Romie J, Rose K, Rosińska D, Rosofsky S, Ross M, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Samajdar A, Sammut L, Sanchez E, Sanchez L, Sanchis-Gual N, Sandberg V, Sanders J, Santiago K, Sarin N, Sassolas B, Sathyaprakash B, Saulson P, Sauter O, Savage R, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield R, Schönbeck A, Schreiber E, Schulte B, Schutz B, Schwalbe S, Scott J, Scott S, Seidel E, Sellers D, Sengupta A, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock D, Shaffer T, Shahriar M, Shaner M, Shao L, Sharma P, Shawhan P, Shen H, Shink R, Shoemaker D, Shoemaker D, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Silva A, Singer L, Singh N, Singhal A, Sintes A, Sitmukhambetov S, Skliris V, Slagmolen B, Slaven-Blair T, Smith J, Smith R, Somala S, Son E, Sorazu B, Sorrentino F, Souradeep T, Sowell E, Spencer A, Srivastava A, Srivastava V, Staats K, Stachie C, Standke M, Steer D, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson S, Stocks D, Stone R, Stops D, Strain K, Stratta G, Strigin S, Strunk A, Sturani R, Stuver A, Sudhir V, Summerscales T, Sun L, Sunil S, Suresh J, Sutton P, Swinkels B, Szczepańczyk M, Tacca M, Tait S, Talbot C, Talukder D, Tanner D, Tápai M, Taracchini A. All-sky search for continuous gravitational waves from isolated neutron stars using Advanced LIGO O2 data. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.100.024004] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
173
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Diaz JC, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Costa CFDS, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Álvarez MD, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Goetz E, Goetz R, Goncharov B, González G, Castro JMG, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hamilton HF, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Hernandez FJ, Heurs M, Hild S, Hinderer T, Hoak D, Hochheim S, Hofman D, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Iess A, Indik N, Ingram C, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Johnson DS, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Key JS, Khalili FY, Khamesra B, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li TGF, Li X, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Hernandez IM, Magaña-Sandoval F, Zertuche LM, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Mills J, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Ng KY, Ng S, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poggiani R, Popolizio P, Porter EK, Possenti L, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Ricker PM, Riemenschneider GM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Robson T, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sarin N, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Shen H, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Slaven-Blair TJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Steltner B, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tamanini N, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westerweck J, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong WK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yam W, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. Tests of General Relativity with GW170817. PHYSICAL REVIEW LETTERS 2019; 123:011102. [PMID: 31386391 DOI: 10.1103/physrevlett.123.011102] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 03/21/2019] [Indexed: 06/10/2023]
Abstract
The recent discovery by Advanced LIGO and Advanced Virgo of a gravitational wave signal from a binary neutron star inspiral has enabled tests of general relativity (GR) with this new type of source. This source, for the first time, permits tests of strong-field dynamics of compact binaries in the presence of matter. In this Letter, we place constraints on the dipole radiation and possible deviations from GR in the post-Newtonian coefficients that govern the inspiral regime. Bounds on modified dispersion of gravitational waves are obtained; in combination with information from the observed electromagnetic counterpart we can also constrain effects due to large extra dimensions. Finally, the polarization content of the gravitational wave signal is studied. The results of all tests performed here show good agreement with GR.
Collapse
|
174
|
Lodhi N, Park J, Kim K, Lee Y, Jeong J, Khalid M. Click chemistry: an efficient strategy for the labeling of proteins. Nucl Med Biol 2019. [DOI: 10.1016/s0969-8051(19)30203-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
175
|
Han S, Chung J, Kim Y, Kim K, Park D, Kwon K, Kim J. Clinicopathologic difference according to gender in gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
176
|
Kim K, Huh J, Kang M. Quality comparison of umbilical cord blood that experienced interruption during cryopreservation. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
177
|
Shin K, Kim K, Cho Y, Ikushiro H, Yano T, Holleran W, Park K, Uchida Y. 298 Both sphingosine kinase 1 and 2 coordinately regulate cathelicidin antimicrobial peptide production during keratinocyte differentiation. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
178
|
Perez M, Abou-El-Seoud D, Kim K, Brown Z, Jain N, Liko Hazizi E, Friedewald S, Robinson J. 773 Skin self-examination for the early detection of melanoma during the mammography experience. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
179
|
Kim Y, Kim K, Ahn H, Kang I, Shin M. 424 Changes in matrix metalloproteinase and collagen transcription through TGF-β/Smad pathway in passaged normal human dermal fibroblasts. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
180
|
Kim J, Byun S, Shin K, Kim DY, Kim T, Kim Y, Lee SY, Kim K. Treatment outcomes after post-operative radiotherapy in triple-negative breast cancer: Multi-institutional retrospective study (KROG 17-05). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz098.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
181
|
Meattini I, Kirova Y, Saieva C, Visani L, Olmetto E, Salvestrini V, Kim J, Jung W, Desideri I, Fourquet A, Poortmans P, Livi L, Kim K. PO-0761 Hypofractionated whole breast irradiation safety after breast-conserving surgery for young patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31181-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
182
|
|
183
|
KIim J, Kim K, Shin K, Kim J, Kim S, Kim T, Kim Y, Park W, Kim J. EP-1279 M neck lymph node positive without distant metastasis in breast cancer: comparison with stage IIIC. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31699-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
184
|
Oh T, Park J, Kim K, Yeaji L, Jung-Won H, Hyo-Seok N. EFFECT OF SEVOFLURANE- VS PROPOFOL-BASED ANESTHESIA ON THE INCIDENCE OF POSTOPERATIVE ACUTE KIDNEY INJURY. Chest 2019. [DOI: 10.1016/j.chest.2019.02.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
185
|
Choi HJ, Cha SJ, Kim K. Glutathione transferase modulates acute ethanol-induced sedation in Drosophila neurones. INSECT MOLECULAR BIOLOGY 2019; 28:246-252. [PMID: 30347459 DOI: 10.1111/imb.12547] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Heavy alcohol consumption leads to neuropathological damage and alcohol use disorder, which affects the health of people and results in a cost burden. However, the genes modulating sensitivity to ethanol remain largely unknown. Here, we identified a novel gene, Drosophila glutathione transferase omega 1 (GstO1), which plays a critical role in regulating sensitivity to ethanol sedation. GstO1 mutant flies showed highly increased ethanol sensitivity. Furthermore, the expression level of GstO1 regulates the behavioural response to ethanol, because decreasing and increasing GstO1 affects sedation sensitivity in a contrasting manner. In addition, the RNA interference-mediated knockdown of GstO1 expression reveals that GstO1 mediates sensitivity to ethanol sedation in neurones, including dopaminergic and serotonergic neurones. Altogether, our findings provide the first evidence for the involvement of glutathione transferase in the response to alcohol in Drosophila and provide a novel mechanistic insight into the toxicity and sensitivity of ethanol exposure.
Collapse
|
186
|
Kim B, Shin K, Chie E, Kim J, Kim K, Kim S. EP-1277 Locoregionally recurrent breast cancer treated with postoperative or salvage radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31697-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
187
|
Kim Y, Seo J, Kim K. Comparison of diagnostic accuracy of malignancy of unenhanced abbreviated MRI with diffusion-weighted images and postcontrast abbreviated breast MRI. Breast 2019. [DOI: 10.1016/s0960-9776(19)30438-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
188
|
Aronberg R, Khaja M, Sherk W, Kim K, Yang B, Fukuhara S, Patel H, Williams D. 03:27 PM Abstract No. 406 Thoracic endovascular aortic repair using a balloon-expandable, re-collapsible sheath: a single-center retrospective analysis. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
189
|
Shaikh R, Kim K. Abstract No. 508 Recalcitrant aneurysmal bone cysts: does cryoablation help? J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
190
|
Kim H, Park W, Choi DH, Ahn SJ, Kim SS, Kim ES, Lee JH, Lee KC, Kim JH, Lee HS, Kim JH, Kim MY, Park HJ, Kim K, Song SH, Kwon J, Lee IJ, Kim TH, Kim TG, Chang AR, Cho O, Jeong BK, Ha B, Lee J, Ki Y. Abstract OT2-04-02: A phase 3 study of post-lumpectomy radiotherapy to whole breast + regional lymph nodes vs whole breast alone for patients with pN1 breast cancer treated with taxane-based chemotherapy (KROG 1701): Trial in progress. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-04-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In patients with early stage breast cancer, regional nodal irradiation (RNI) is added to whole breast irradiation (WBI) in order to control microscopic regional disease and to prevent systemic spread of cancer. According to recent randomized trials (MA.20 and EORTC 22922-10925), prophylactic RNI was associated with improvement in disease-free survival (DFS) in the patients with high-risk node negative or pN1 breast cancer. However, systemic agents now known to improve loco-regional control, such as taxane or endocrine therapy, were prescribed to a small percentage of patients in the studies. The benefit of RNI found in the previous studies might be attributed to incorporation of less effective systemic treatments. The impact of prophylactic RNI in pN1 breast cancer should be evaluated in the patients receiving modern systemic treatment. The current study was conducted to compare the effect of post-lumpectomy WBI vs WBI plus RNI on DFS in pN1 breast cancer patients who received adjuvant taxane-based chemotherapy.
Methods
This study is a multicenter, phase 3, randomized controlled non-inferiority trial (NCT03269981). Eligibility criteria are ≥ 20 years female; pathologically proven invasive carcinoma of the breast; one to three positive axillary lymph nodes (pN1) in pathologic specimen; receiving breast-conserving surgery followed by taxane-based chemotherapy; having adjuvant endocrine therapy or anti-HER2 treatment according to molecular subtype of tumor. Patients are randomly assigned in a 1:1 ratio to receive WBI or WBI plus RNI. Patient randomization was stratified by molecular subtype of tumor (i.e. luminal A/luminal B/luminal HER2/HER2-enriched/triple-negative) and methods of axillary management (i.e. sentinel lymph node biopsy/axillary lymph node dissection). The primary outcome is DFS. The secondary outcomes include DFS according to molecular subtype, treatment-related toxicity, and patient's quality of life per EORTC QLQ-C30 and QLQ-BR23. Patients will be followed for survival and disease recurrence for seven years. A total of 1,926 patients are planned to be enrolled, with recruitment initiated in April 2017. As of June 2018, a total of 236 patients were enrolled.
Acknowledgement
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (grant number: HA17C0043010018).
Citation Format: Kim H, Park W, Choi DH, Ahn SJ, Kim SS, Kim ES, Lee JH, Lee KC, Kim JH, Lee H-S, Kim JH, Kim MY, Park HJ, Kim K, Song SH, Kwon J, Lee IJ, Kim TH, Kim TG, Chang AR, Cho O, Jeong BK, Ha B, Lee J, Ki Y. A phase 3 study of post-lumpectomy radiotherapy to whole breast + regional lymph nodes vs whole breast alone for patients with pN1 breast cancer treated with taxane-based chemotherapy (KROG 1701): Trial in progress [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-04-02.
Collapse
|
191
|
Jeong S, Kim Y, Kim K. Abstract P5-01-01: The effectiveness of breast ultrasonography in cancer screening: A comparison with mammography. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose
Mammography(MMG) is a measure of screening that is proven to be effective in lowering death rate in breast cancer validated by randomized control trials. Recently, the number of incidence of breast cancer in Korean women is showing ascending tendency, and also as compared to those in North American and European countries, prevalence age tends to be lower. Since they tend to have much dense breast, MMG alone can hardly be considered as a sufficient measure of breast cancer screening.
The purpose of the study is to study the effectiveness of breast ultrasonography(US) in breast cancer screening in Korean women by investigating the ratio of patients who are diagnosed as malignant in breast US over those who are diagnosed as negative or benign(category 1 and 2) and dense breast(category 0) in MMG.
Materials and Methods
We conducted the retrograde study over 2776 female subjects who had undergone screening MMG in single center in South Korea during the period between Jan, 1st 2010 to Dec, 31st 2016. Female patients are categorized according to BI-RAD category. 164 of subjects were previously undergone a breast cancer surgery, which made them eliminated from the list, and 2612 subjects are finally selected.
Results
Some more 33 subjects are excluded from the list and rest 2579 subject had undergone breast US. Among these, 1133 subjects (43.9%, 1133/2579) correspond to dense breast of BI-RADS category 0, while 303 of them are suspected of category 4 or more. The subjects corresponding to category 1 to 3 are 663, 251 and 229 respectively. 307 of 1133 subjects in category 0 are confirmed as having suspicious lesion based on findings of breast US. Among them, 66 subjects are identified as malignant based on biopsy, which accounts for 5.8% (66/1133). 104 subjects in category 1, are confirmed to have lesions based on findings of breast US, where 25 alone were identified as malignant (3.8%, 25/663). Likewise, 10 (4.0%, 10/251) in category 2 and 13 (5.7%, 13/229) in category 3 are identified.
Subject categorization by BI-RAD systemCategory 0dense breast983 dense breast with calcification94 dense breast with probable mass28 others28 total113343.9%Category 1 66325.7%Category 2 2519.7%Category 3 2298.9%Category 4 or more 30311.7%total 2579100.0%
Malignancy ratio of each category after biopsy totalsuspicious lesion on breast USbiopsy benignmalignantmalignancy ratioCategory 01133307241665.8% (66/1133)Category 1663104792525 3.8% (25/663)Category 22514131104.0% (10/251)Category 32297259135.7% (13/229)
Conclusion
It appears that 43.9% of total 2579 subjects undergone MMG and breast US are confirmed as dense breast in category 0 and 5.8% of them are diagnosed as breast cancer according to breast US and biopsy. Likewise, for those who are considered as either category 1 or 2, which is negative or benign lesion category, 3.8% are diagnosed as breast cancer. As it is appeared in this study, cancer detection can be more effective in parallel measure of MMG and breast US rather than MMG alone, especially for breast cancer screening of Korean female subjects.
Citation Format: Jeong S, Kim Y, Kim K. The effectiveness of breast ultrasonography in cancer screening: A comparison with mammography [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-01-01.
Collapse
|
192
|
Kim K, Jeong Y, Shin KH, Kim JH, Ahn SD, Kim SS, Suh CO, Kim YB, Choi DH, Park W, Cha J, Chun M, Lee DS, Lee SY, Kim JH, Park HJ. Abstract P3-12-12: Impact of regional nodal irradiation for breast cancer patients with supraclavicular and/or internal mammary lymph node involvement: A multicenter, retrospective study (KROG 16-14). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-12-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To evaluate the treatment outcomes of radiotherapy (RT) for breast cancer with ipsilateral supraclavicular (SCL) and/or internal mammary (IMN) lymph node involvement.
Methods: A total of 353 patients from 11 institutions were included. One hundred and thirty-six patients had SCL involvement, 148 had IMN involvement, and 69 had both. All patients received neoadjvant systemic therapy followed by breast conserving surgery or mastectomy, and postoperative RT to whole breast/chest wall. As for regional lymph node irradiation, SCL RT was given to 344 patients, and IMN RT to 236 patients. The median RT dose was 50.4 Gy.
Results: The median follow-up duration was 61 months (range, 7-173). In-field progression was present in SCL (n=20) and/or IMN (n=7). The 5-year disease-free survival (DFS) and overall survival rates were 57.8% and 75.1%, respectively. On multivariate analysis, both SCL/IMN involvement, number of axillary lymph node ≥4, triple negative subtype, and mastectomy were significant adverse prognosticators for DFS (p = 0.022, 0.001, 0.001, and 0.004, respectively). Regarding the impact of regional nodal irradiation, SCL RT dose ≥54 Gy was not associated with DFS (5-yr rate, 52.9% vs. 50.9%, p = 0.696) in SCL-involved patients, and the receipt of IMN RT was not associated with DFS (5-yr rate, 56.1% vs. 78.1%, p = 0.099) in IMN-involved patients.
Conclusion: Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an acceptable in-field regional control rate in patients with SCL and/or IMN involvement. However, a higher RT dose to SCL or IMN RT was not associated with the improved DFS in these patients.
Citation Format: Kim K, Jeong Y, Shin KH, Kim JH, Ahn SD, Kim SS, Suh C-O, Kim YB, Choi DH, Park W, Cha J, Chun M, Lee DS, Lee SY, Kim JH, Park HJ. Impact of regional nodal irradiation for breast cancer patients with supraclavicular and/or internal mammary lymph node involvement: A multicenter, retrospective study (KROG 16-14) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-12.
Collapse
|
193
|
Kim M, Kim K, Tutuncuoglu B, Soucheray M, Swaney D, Zheng F, Park J, O'Leary P, Coppé JP, van 't Veer L, Ashworth A, Ideker T, Krogan N. Abstract P6-06-01: Analyzing the physical and functional protein interaction landscape of breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A key unanswered question in cancer genetics is how different mutations, dispersed across a multitude of genes, elicit similar pathology and patient outcomes. The answer may lie in understanding the molecular networks and protein complexes (i.e. signaling pathways, chromatin architecture, etc) in cancer and mapping mutated genes into the complexes and pathways in which they function. Determining how systematic interaction networks are wired in cancer cells and how different mutations perturb these networks will guide the search for new cancer genes and provide a platform for integrating patient data to make biological and clinical predictions more accurate. The goal of this study is to uncover the comprehensive protein-protein interaction networks and pathways in various breast cancer subtypes to better understand how mutated cancer genes and genomes hijack and re-wire pathways and complexes during the course of breast tumorigenesis.
Here we catalog protein-protein interactions for 40 genes recurrently mutated in breast cancer, using affinity purification and mass spectrometry. To identify co-associated proteins, cDNA clones expressing each protein were tagged with 3xFLAG at either N or C-terminus and introduced into MCF10A (non-tumorigenic “healthy” control), MCF7 (luminal A subtype), and MDA-MB-231 (claudin-low) cells using doxycycline-inducible lentiviral vectors. For proteins with prevalent pathogenic mutations (e.g. PIK3CA-H1047R, BRCA1-C61G), mutant cDNA clones were also analyzed in parallel. Our interaction network reveals subtype and mutation-specific protein-protein interactions, many of which are not previously reported. Given that genes encoding components of a protein complex or a biological pathway often share similar phenotype upon genetic perturbation, we genetically knocked out genes interacting with DNA damage response (DDR) proteins using CRISPR/Cas9, and found multiple novel interacting genes whose knockout results in significant PARPi (olaparib) and/or cisplatin sensitivity. This result not only functionally validates the physical protein interactions, but also demonstrates that our interactome mapping approach can helps identify newdruggable vulnerabilities in cancer cells.
We anticipate the breast cancer interactome study will uncover aberrant pathways and protein complexes uniquely operating in breast cancer cells, and thus pinpoint proteins that may potentially serve as distinct biomarkers or therapeutic targets for tumors having the same or similar subtypes and/or genomic mutations.
Citation Format: Kim M, Kim K, Tutuncuoglu B, Soucheray M, Swaney D, Zheng F, Park J, O'Leary P, Coppé J-P, van 't Veer L, Ashworth A, Ideker T, Krogan N. Analyzing the physical and functional protein interaction landscape of breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-06-01.
Collapse
|
194
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Costa CFDS, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hamilton HF, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Hernandez FJ, Heurs M, Hild S, Hinderer T, Hoak D, Hochheim S, Hofman D, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Iess A, Indik N, Ingram C, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Johnson DS, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Key JS, Khalili FY, Khamesra B, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li TGF, Li X, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Mills J, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Ng KY, Ng S, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poggiani R, Popolizio P, Porter EK, Possenti L, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Ricker PM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Robson T, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sarin N, Sassolas B, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Shen H, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Slaven-Blair TJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Steltner B, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsuna D, Tsukada L, Tuyenbayev D, Ueno K, Ugolini D, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westerweck J, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong WK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yam W, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J, Weinberg NN. Constraining the p-Mode-g-Mode Tidal Instability with GW170817. PHYSICAL REVIEW LETTERS 2019; 122:061104. [PMID: 30822067 DOI: 10.1103/physrevlett.122.061104] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 10/30/2018] [Indexed: 06/09/2023]
Abstract
We analyze the impact of a proposed tidal instability coupling p modes and g modes within neutron stars on GW170817. This nonresonant instability transfers energy from the orbit of the binary to internal modes of the stars, accelerating the gravitational-wave driven inspiral. We model the impact of this instability on the phasing of the gravitational wave signal using three parameters per star: an overall amplitude, a saturation frequency, and a spectral index. Incorporating these additional parameters, we compute the Bayes factor (lnB_{!pg}^{pg}) comparing our p-g model to a standard one. We find that the observed signal is consistent with waveform models that neglect p-g effects, with lnB_{!pg}^{pg}=0.03_{-0.58}^{+0.70} (maximum a posteriori and 90% credible region). By injecting simulated signals that do not include p-g effects and recovering them with the p-g model, we show that there is a ≃50% probability of obtaining similar lnB_{!pg}^{pg} even when p-g effects are absent. We find that the p-g amplitude for 1.4 M_{⊙} neutron stars is constrained to less than a few tenths of the theoretical maximum, with maxima a posteriori near one-tenth this maximum and p-g saturation frequency ∼70 Hz. This suggests that there are less than a few hundred excited modes, assuming they all saturate by wave breaking. For comparison, theoretical upper bounds suggest ≲10^{3} modes saturate by wave breaking. Thus, the measured constraints only rule out extreme values of the p-g parameters. They also imply that the instability dissipates ≲10^{51} erg over the entire inspiral, i.e., less than a few percent of the energy radiated as gravitational waves.
Collapse
|
195
|
Lim A, Kim DW, Kim K, Kim RD, Bottiglieri SM. Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.251] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
251 Background: Combination chemotherapy with nab-paclitaxel/gemcitabine is a standard of care option in metastatic pancreatic cancer management with increasing use due to an improvement in median overall survival of 1.8 months compared to gemcitabine alone. It is also used in practice in the second and third-line settings for patients that have progressed on fluorouracil based regimens. As the utility of this combination chemotherapy has grown, dose intensity (DI) in relation to survival outcome is an important measure for real world application. Methods: Fifty-six patients that were 18 years or older with metastatic pancreatic cancer treated with nab-paclitaxel/gemcitabine as first-line therapy from January 1, 2013 to December 31, 2014 at Moffitt Cancer Center were identified through medical records. The subjects were retrospectively reviewed, and demographic, treatment outcomes (survival and progression), and DI were collected. Overall survival was calculated with Kaplan Meier survival curves. Multi-Cox regression models estimated multivariable-adjusted hazard ratio with 95% confidence intervals. Results: There was no significant relationship between receiving a DI > 85% regimen in relation to independent variables of age > 65, sex, primary site, and known distant metastasis; however DI > 85% was significant for patients that received additional chemotherapy following nab-paclitaxel/gemcitabine (p = 0.044). The DI > 85% group compared to the < 85% group had a hazard ratio (HR) for all-cause mortality of 0.285 (0.106-0.764, p = 0.013). Six and 12-month survival were higher in the DI > 85% group (p = 0.009, p = 0.02 respectively). Conclusions: DI > 85% for nab-paclitaxel/gemcitabine compared to DI < 85% may have a lower all-cause mortality and higher 6 and 12-month survival.
Collapse
|
196
|
Jeon K, Yoon JW, Suh GY, Kim J, Kim K, Yang M, Kim H, Kwon OJ, Shims YM. Risk Factors for Post-pneumonectomy Acute Lung Injury/Acute Respiratory Distress Syndrome in Primary Lung Cancer Patients. Anaesth Intensive Care 2019; 37:14-9. [DOI: 10.1177/0310057x0903700110] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
197
|
Lee S, Lee H, Park J, Yoon S, So B, Seo H, Kim K, Yoo M, Cho Y, Hyun B. Seroprevalence of Anaplasma phagocytophilum, Borrelia burgdorferi, baBesia gibsoni, Ehrlichia canis and Ehrlichia chaffeensis in dogs from the republic of Korea. J Comp Pathol 2019. [DOI: 10.1016/j.jcpa.2018.10.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
198
|
Conradi L, Hilker M, Kempfert J, Börgermann J, Treede H, Holzhey D, Schröfel H, Kim K, Schäfer U, Wünsch D, Walther T. One-Year Outcomes following Transapical Delivery of a Novel, Low-Profile Self-expandable Transcatheter Valve: Results from the ACURATE Neo TA Study. Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
199
|
Kim K, Sinha J, Salazar A, Musgrave C, Stansbury J. Dark-curing photoinitiators that extend the cure depth in composite materials. Dent Mater 2019. [DOI: 10.1016/j.dental.2019.08.092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
200
|
Josic T, Koehne J, Liebetrau C, Schönburg M, Kim K, Doss M. Up to 7-Year Follow-up of Bicuspid Aortic Valves (BAV) Undergoing TAVI versus Surgical Aortic Valve Replacement (SAVR). Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|